SCHEMBL31023536

SCHEMBL31023536

O=C(NCc1ccc(-c2ccccc2)cc1)c1cnc(Cl)nc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 3/20 0.69
EPHX2 P34913 2/20 0.62
NR1H4 Q96RI1 2/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
HDAC3 O15379 2/20 0.61
HDAC1 Q13547 2/20 0.61
HDAC2 Q92769 2/20 0.61
HDAC6 Q9UBN7 2/20 0.61
HDAC4 P56524 1/20 0.61
HDAC7 Q8WUI4 1/20 0.61
HDAC10 Q969S8 1/20 0.61
HDAC11 Q96DB2 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC9 Q9UKV0 1/20 0.61
HDAC5 Q9UQL6 1/20 0.61
MMP13 P45452 1/20 0.59
SCN2A Q99250 1/20 0.57
SCN10A Q9Y5Y9 1/20 0.57
TRPV1 Q8NER1 1/20 0.57
ROCK2 O75116 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023556 0.86 L3MBTL1 (0.84) HPGDSEPHX2NR1H4L3MBTL1HDAC3
SCHEMBL31023575 0.85 HPGD (0.63) HPGDSEPHX2L3MBTL1MMP13SMN1; SMN2
SCHEMBL4636511 0.82 HPGDS (1.00) HPGDSEPHX2NR1H4L3MBTL1HDAC3
SCHEMBL1926318 0.81 EPHX2 (0.77) EPHX2NR1H4HDAC3HDAC1HDAC2
SCHEMBL31023490 0.79 SMN1; SMN2 (0.61) HPGDSEPHX2NR1H4L3MBTL1HDAC3
SCHEMBL16496250 0.79 HPGDS (0.82) HPGDSEPHX2NR1H4L3MBTL1HDAC3
SCHEMBL539059 0.78 EPHX2 (0.84) HPGDSEPHX2NR1H4HDAC3HDAC1
SCHEMBL4776301 0.78 HPGDS (0.79) HPGDSEPHX2NR1H4L3MBTL1HDAC3
SCHEMBL31023627 0.77 EGLN1 (0.61) HPGDSEPHX2NR1H4L3MBTL1HDAC3
SCHEMBL31023451 0.77 EPHX2 (0.62) HPGDSEPHX2NR1H4HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027096-A1 PHD INHIBITORS UNIV OXFORD INNOVATION LTD (GB) 2026-01-29 US disclosed
EP-4655294-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 EP disclosed
EP-4655288-A1 PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 EP disclosed
WO-2024157019-A1 PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 WO disclosed
WO-2024157014-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027096-A1 PHD INHIBITORS HIF1AN, HIF1A, EGLN1 HPGDS 69/4885EPHX2 1495/4885NR1H4 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.